Effects of FR-91 on Immune Cells from Healthy Individuals and from Patients with Non-Hodgkin Lymphoma

Table 2

Effect of FR-91 on peripheral blood mononuclear cell (PBMC) subsets from NHL patients.

	CD3/control	CD3/FR-91 10 𝜇g/mL	CD3/FR-91 25 𝜇g/mL
X*	57.73	71.09	69.45
SD^**	3.97	4.67	6.72
CV^***	0.06	0.06	0.09
P^****		.001	.002
	HLA-DR/control	HLA-DR/FR-91 10 𝜇g/mL	HLA-DR/FR-91 25 𝜇g/mL
X	8.5	5.66	6.36
SD	2.08	2.18	4.16
CV	0.24	0.38	0.65
P		.002	.109
	CD4/control	CD4/FR-91 10 𝜇g/mL	CD4/FR-91 25 𝜇g/mL
X	36.28	48.39	47.41
SD	8.6	6.27	4.95
CV	0.23	0.13	0.1
P		.001	.002
	CD25/control	CD25/FR-91 10 𝜇g/mL	CD25/FR-91 25 𝜇g/mL
X	6.12	5.62	5.47
SD	4.34	3.84	2.51
CV	0.7	0.68	0.46
P		.32	.41
	CD8/control	CD8/FR-91 10 𝜇g/mL	CD8/FR-91 25 𝜇g/mL
X	26.96	23.47	23.96
SD	7.52	4.22	3.58
CV	0.27	0.17	0.15
P		.17	.11
	CD69/control	CD69/FR-91 10 𝜇g/mL	CD69/FR-91 25 𝜇g/mL
X	22.37	12.83	13.33
SD	9.63	4.06	4.31
CV	0.43	0.31	0.32
P		.01	.008

𝑛=15;  *mean; ^**standard deviation; ^***coefficient of variation; ^****<.05: significant values.